ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute ...
A new logic-level approach directly impacts board-level performance and complexity. By optimizing interconnects, fanouts and signal structures before schematic capture, a new gate-level synthesis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results